Guía Clínica
Versión actualizada - 2010
Guía para países de bajos ingresos. 2 edición
WHO Zika Virus - Questions & Answers (Spanish)
This Toolkit is intended to guide humanitarian programme managers and healthcare providers to ensure that sexual and reproductive health interventions put into place both during and after a crisis are responsive to the unique needs of adolescents.
A practical tool to help health workers in the clinical and operational management of multidrug-resistant tuberculosis with special focus on the introduction, implementation and management of the nine-month treatment regimen.
CORONAVIRUS COVID-19 Manejo Clínico en Pediatría
Paraguay
Manejo Clínico en COVID- 19 Recomendaciones para el manejo de pacientes
adultos con el diagnóstico de COVID‐19
Servicio de Infectología Clínica–Instituto de
Medicina Tropical Abril-2020
Paraguay
El Salvador's response to tuberculosis control: A sustainability analysis
Clinical guidelines for the comprehensive care of patients with drug-resistant tuberculosis
Herramientas de adaptación del Plan Estratégico Colombia Libre de Tuberculosis post 2015
Convenio 519 de 2015 Colombia, septiembre de 2016
Esta carpeta ofrece información básica acerca de la estrategia de tamizaje basada en el test de VPH. Tiene como principales destinatariosa los integrantes del equipo de salud que realizan las tomas de las muestras para el tamizaje en las provincias que incorporaron esta nueva tecnología [ginecól...ogas/os, Lic. en obstetricia,obstétricas/os, médicas/os generalistas, enfermeras/os, etc.].
more
Reseña normativa de la OMS:
Chagas disease (CD) is caused by the parasite Trypanosoma cruzi, and it is endemic in Central, South America, Mexico and the
South of the United States. It is an important cause of early mortality and morbidity, and it is associated with poverty and stigma. A third of
the cases evolve into chronic... cardiomyopathy and gastrointestinal disease. The infection is transmitted vertically and by blood/organ
donation and can reactivate with immunosuppression. Case identification requires awareness and screening programmes targeting the
population at risk (women in reproductive age, donors, immunocompromised patients). Treatment with benznidazole or nifurtimox is most
effective in the acute phase and prevents progression to chronic phase when given to children. Treating women antenatally reduces but does
not eliminate vertical transmission. Treatment is poorly tolerated, contraindicated during pregnancy, and has little effect modifying the
disease in the chronic phase. Screening is easily performed with serology. Migration has brought the disease outside of the endemic
countries, where the transmission continues vertically and via blood and tissue/organ donations. There are more than 32 million migrants
from Latin America living in non-endemic countries. However, the infection is massively underdiagnosed in this setting due to the lack of
awareness by patients, health authorities and professionals. Blood and tissue donation screening policies have significantly reduced
transmission in endemic countries but are not universally established in the non-endemic setting. Antenatal screening is not commonly
done. Other challenges include difficulties accessing and retaining patients in the healthcare system and lack of specific funding for the
interventions. Any strategy must be accompanied by education and awareness campaigns directed to patients, professionals and policy
makers. The involvement of patients and their communities is central and key for success and must be sought early and actively. This review
proposes strategies to address challenges faced by non-endemic countries
more